{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:29:06Z","timestamp":1789615746121,"version":"build-2803163510"},"reference-count":309,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LTGY24H170001"],"award-info":[{"award-number":["LTGY24H170001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82474239"],"award-info":[{"award-number":["82474239"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.phrs.2026.108316","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:38:03Z","timestamp":1782171483000},"page":"108316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Chimeric antigen receptor-T cell therapy-induced cardiotoxicity: Pathophysiological mechanisms and pharmacological intervention strategies"],"prefix":"10.1016","volume":"230","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0093-9661","authenticated-orcid":false,"given":"Linhao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenfeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhou","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.phrs.2026.108316_bib1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"26","key":"10.1016\/j.phrs.2026.108316_bib2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.phrs.2026.108316_bib3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.phrs.2026.108316_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26178388","article-title":"Lymphoid and Myeloid Proliferations After Chimeric Antigen Receptor (CAR) T-Cell Therapy: The Pathologist's Perspective","volume":"26","author":"Zhou","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108316_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103229","article-title":"Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Shu","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"12","key":"10.1016\/j.phrs.2026.108316_bib6","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jamaoncol.2024.4879","article-title":"Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical Trial","volume":"10","author":"Li","year":"2024","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s40164-025-00710-y","article-title":"Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed\/refractory multiple myeloma","volume":"14","author":"Chen","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108316_bib8","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/bloodadvances.2024014182","article-title":"Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"9","author":"Wang","year":"2025","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.phrs.2026.108316_bib9","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell."},{"issue":"20","key":"10.1016\/j.phrs.2026.108316_bib10","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/eurheartj\/ehac106","article-title":"Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies","volume":"43","author":"Totzeck","year":"2022","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.phrs.2026.108316_bib11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phrs.2026.108316_bib13","article-title":"Therapeutic Potential of TNFalpha and IL1beta Blockade for CRS\/ICANS in CAR-T Therapy via Ameliorating Endothelial Activation","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40164-025-00638-3","article-title":"Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults","volume":"14","author":"Galan-Gomez","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"issue":"14","key":"10.1016\/j.phrs.2026.108316_bib15","article-title":"Cytokine-engineered chimeric antigen receptor-T cell therapy: how to balance the efficacy and toxicity","volume":"13","author":"Zhang","year":"2026","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"11","key":"10.1016\/j.phrs.2026.108316_bib16","first-page":"2346","article-title":"Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen","volume":"55","author":"Bejcek","year":"1995","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.phrs.2026.108316_bib17","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/leu.2017.57","article-title":"Fully human CD19-specific chimeric antigen receptors for T-cell therapy","volume":"31","author":"Sommermeyer","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.phrs.2026.108316_bib18","doi-asserted-by":"crossref","first-page":"9207","DOI":"10.1002\/jcp.27599","article-title":"Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells","volume":"234","author":"Mirzaei","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib19","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ymthe.2021.08.033","article-title":"A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL","volume":"30","author":"Zanetti","year":"2022","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib20","doi-asserted-by":"crossref","first-page":"917","DOI":"10.4143\/crt.2021.399","article-title":"Outcomes of Anti-CD19 CAR-T Treatment of Pediatric B-ALL with Bone Marrow and Extramedullary Relapse","volume":"54","author":"Wan","year":"2022","journal-title":"Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.phrs.2026.108316_bib21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T Cells Expressing CD19\/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib22","doi-asserted-by":"crossref","first-page":"888","DOI":"10.4049\/jimmunol.165.2.888","article-title":"Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells","volume":"165","author":"Cochlovius","year":"2000","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib23","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2141.2005.05414.x","article-title":"Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16)","volume":"130","author":"Bruenke","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cells12020248","article-title":"A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2(+) Solid Cancer","volume":"12","author":"Hombach","year":"2023","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.phrs.2026.108316_bib25","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/bjh.19631","article-title":"Development of novel humanized CD19\/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms","volume":"205","author":"Wu","year":"2024","journal-title":"Br. J. Haematol."},{"issue":"1-2","key":"10.1016\/j.phrs.2026.108316_bib26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jim.2004.12.003","article-title":"Sheep red blood cells armed with anti-CD20 single-chain variable fragments (scFvs) fused to a glycosylphosphatidylinositol (GPI) anchor: a strategy to target CD20-positive tumor cells","volume":"297","author":"Hamdy","year":"2005","journal-title":"J. Immunol. Methods"},{"issue":"4","key":"10.1016\/j.phrs.2026.108316_bib27","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.bbrc.2016.03.124","article-title":"Tetravalent anti-CD20\/CD3 bispecific antibody for the treatment of B cell lymphoma","volume":"473","author":"Lu","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4103\/RPS.RPS_248_24","article-title":"Expression and functional characterization of an anti-CD22 scFv targeting B-cell malignancies","volume":"20","author":"Gholizadeh","year":"2025","journal-title":"Res. Pharm. Sci."},{"issue":"24","key":"10.1016\/j.phrs.2026.108316_bib29","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1007\/s00253-014-6071-2","article-title":"High efficient expression of a functional humanized single-chain variable fragment (scFv) antibody against CD22 in Pichia pastoris","volume":"98","author":"Zarei","year":"2014","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108316_bib30","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jcyt.2023.01.002","article-title":"T-cell engineered with a fully humanized B-cell maturation antigen-specific T-cell antigen coupler receptor effectively target multiple myeloma","volume":"25","author":"Bezverbnaya","year":"2023","journal-title":"Cytotherapy"},{"issue":"22","key":"10.1016\/j.phrs.2026.108316_bib31","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.phrs.2026.108316_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cells14241944","article-title":"Comparing a Novel Anti-BCMA NanoCAR with a Conventional ScFv-Based CAR for the Treatment of Multiple Myeloma","volume":"14","author":"Jassin","year":"2025","journal-title":"Cells"},{"issue":"1-2","key":"10.1016\/j.phrs.2026.108316_bib33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0022-1759(01)00298-8","article-title":"An improved procedure for the generation of recombinant single-chain Fv antibody fragments reacting with human CD13 on intact cells","volume":"251","author":"Peipp","year":"2001","journal-title":"J. Immunol. Methods"},{"issue":"11","key":"10.1016\/j.phrs.2026.108316_bib34","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00432-017-2468-5","article-title":"Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13-ETA' and the bispecific scFv [13xds16","volume":"143","author":"Grieger","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41416-018-0341-1","article-title":"High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy","volume":"120","author":"Rataj","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40164-023-00437-8","article-title":"A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models","volume":"12","author":"Chan","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108316_bib37","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"issue":"1-2","key":"10.1016\/j.phrs.2026.108316_bib38","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ijpharm.2016.11.008","article-title":"Development of a Targeted anti-HER2 scFv Chimeric Peptide for Gene Delivery into HER2-Positive Breast Cancer Cells","volume":"515","author":"Cheraghi","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib39","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3674","article-title":"Construction and evaluation of a novel humanized HER2-specific chimeric receptor","volume":"16","author":"Sun","year":"2014","journal-title":"Breast Cancer Res."},{"issue":"12","key":"10.1016\/j.phrs.2026.108316_bib40","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/s41419-021-04100-0","article-title":"HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer","volume":"12","author":"Xu","year":"2021","journal-title":"Cell. Death Dis."},{"issue":"10","key":"10.1016\/j.phrs.2026.108316_bib41","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s13238-017-0384-8","article-title":"Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo","volume":"9","author":"Song","year":"2018","journal-title":"Protein Cell."},{"issue":"10","key":"10.1016\/j.phrs.2026.108316_bib42","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-16-1860","article-title":"Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting","volume":"23","author":"Slaney","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.phrs.2026.108316_bib43","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.7150\/thno.26585","article-title":"Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma","volume":"8","author":"Cheal","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.phrs.2026.108316_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2023.113456","article-title":"A cell-based subtractive panning strategy for selection of conformation-specific single-chain variable-fragment (scFv) against dimerization domain of EGFR","volume":"515","author":"Valadan","year":"2023","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40478-025-01965-6","article-title":"Development of CAR-T cell therapy for NF1\/SWN-related nerve sheath tumor treatment","volume":"13","author":"Tang","year":"2025","journal-title":"Acta Neuropathol. Commun."},{"issue":"24","key":"10.1016\/j.phrs.2026.108316_bib46","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1158\/1078-0432.CCR-19-1479","article-title":"Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors","volume":"25","author":"Balakrishnan","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.phrs.2026.108316_bib47","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.phrs.2026.108316_bib48","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/s41551-024-01258-8","article-title":"Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders","volume":"8","author":"Xia","year":"2024","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib49","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12951-024-02414-7","article-title":"Anti-EGFR ScFv functionalized exosomes delivering LPCAT1 specific siRNAs for inhibition of lung cancer brain metastases","volume":"22","author":"Jiang","year":"2024","journal-title":"J. Nanobiotechnology"},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib50","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41419-017-0238-6","article-title":"Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice","volume":"9","author":"Li","year":"2018","journal-title":"Cell. Death Dis."},{"issue":"5","key":"10.1016\/j.phrs.2026.108316_bib51","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s11427-016-5023-8","article-title":"Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed\/refractory non-small cell lung cancer","volume":"59","author":"Feng","year":"2016","journal-title":"Sci. China Life Sci."},{"issue":"7","key":"10.1016\/j.phrs.2026.108316_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13071598","article-title":"Interleukin 21-Armed EGFR-VHH-CAR-T Cell Therapy for the Treatment of Esophageal Squamous Cell Carcinoma","volume":"13","author":"Zhang","year":"2025","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.phrs.2026.108316_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13051027","article-title":"A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action","volume":"13","author":"Mohan","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib54","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-024-01538-5","article-title":"Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma","volume":"17","author":"Long","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108316_bib55","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1158\/2326-6066.CIR-18-0044","article-title":"Selective targeting of glioblastoma with EGFRvIII\/EGFR bitargeted chimeric antigen receptor T Cell","volume":"6","author":"Jiang","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"485","key":"10.1016\/j.phrs.2026.108316_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.phrs.2026.108316_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002151","article-title":"VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding","volume":"9","author":"Lanitis","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib58","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/mt.2011.256","article-title":"Jr., Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor","volume":"20","author":"Lanitis","year":"2012","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2026.108316_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cells9051182","article-title":"Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold","volume":"9","author":"Fujiwara","year":"2020","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.phrs.2026.108316_bib60","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the Antigen Density Requirement for CAR T-cell Activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.phrs.2026.108316_bib61","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1007\/s00262-022-03195-4","article-title":"Chimeric antigen receptor clustering via cysteines enhances T-cell efficacy against tumor","volume":"71","author":"Wang","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"Pt A","key":"10.1016\/j.phrs.2026.108316_bib62","article-title":"A C(H)2C(H)3 hinge region enhances the cytotoxicity of anti-CD5 CAR-T cells targeting T cell acute lymphoblastic leukemia","volume":"124","author":"Wu","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib63","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/s41467-023-37616-4","article-title":"The IgG4 hinge with CD28 transmembrane domain improves V(H)H-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.phrs.2026.108316_bib64","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells","volume":"19","author":"Hudecek","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108316_bib65","first-page":"697","article-title":"Low levels of neurologic toxicity with retained anti-lymphoma activity in a phase i clinical trial of t cells expressing a novel anti-CD19 CAR, 60th ASH Annual Meeting and Exposition","author":"Brudno","year":"2018","journal-title":"Blood San. Diego CA"},{"issue":"11","key":"10.1016\/j.phrs.2026.108316_bib66","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13010038","article-title":"The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities","volume":"13","author":"Davey","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.phrs.2026.108316_bib68","article-title":"How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy, J Cell Physiol 231(12) (2016) 2590\u20138.[69] G. Bernard, L. Evgin, Non-signaling but all important: how the linker, hinge, and transmembrane domains in the CAR hold it all together","volume":"16","author":"Gacerez","year":"2025","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.phrs.2026.108316_bib69","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.4049\/jimmunol.0901766","article-title":"The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR\/CD3 complex","volume":"184","author":"Bridgeman","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2026.108316_bib70","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.phrs.2026.108316_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115973","article-title":"CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients","volume":"44","author":"Cook","year":"2025","journal-title":"Cell. Rep."},{"issue":"4","key":"10.1016\/j.phrs.2026.108316_bib72","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/onci.19855","article-title":"OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells","volume":"1","author":"Hombach","year":"2012","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.phrs.2026.108316_bib73","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4161\/onci.19458","article-title":"Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy","volume":"1","author":"Song","year":"2012","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.phrs.2026.108316_bib74","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","article-title":"ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells","volume":"124","author":"Guedan","year":"2014","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.phrs.2026.108316_bib75","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-18-2559","article-title":"Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells","volume":"25","author":"Drent","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108316_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.750478","article-title":"Double Strike Approach for Tumor Attack: Engineering T Cells Using a CD40L:CD28 Chimeric Co-Stimulatory Switch Protein for Enhanced Tumor Targeting in Adoptive Cell Therapy","volume":"12","author":"Olguin-Contreras","year":"2021","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108316_bib77","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/j.ymthe.2021.04.038","article-title":"Composite CD79A\/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival","volume":"29","author":"Julamanee","year":"2021","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.phrs.2026.108316_bib78","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1097\/MS9.0000000000001375","article-title":"Toxicities of CAR T-cell therapy: a review of current literature","volume":"85","author":"Asghar","year":"2023","journal-title":"Ann. Med. Surg. (Lond. )"},{"issue":"13","key":"10.1016\/j.phrs.2026.108316_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133476","article-title":"Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy","volume":"15","author":"Zheng","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.phrs.2026.108316_bib80","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.phrs.2026.108316_bib81","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108316_bib82","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.omto.2022.10.006","article-title":"Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot project","volume":"27","author":"Foster","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"issue":"12","key":"10.1016\/j.phrs.2026.108316_bib83","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"14","key":"10.1016\/j.phrs.2026.108316_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143534","article-title":"IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15\/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation","volume":"13","author":"Battram","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9967","key":"10.1016\/j.phrs.2026.108316_bib85","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.phrs.2026.108316_bib86","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib87","doi-asserted-by":"crossref","DOI":"10.2174\/1573403X18666220623152350","article-title":"Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy","volume":"19","author":"Gill","year":"2023","journal-title":"Curr. Cardiol. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib88","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T Cell Therapy-Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity?","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"22","key":"10.1016\/j.phrs.2026.108316_bib89","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/eurheartj\/ehad117","article-title":"Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients","volume":"44","author":"Mahmood","year":"2023","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib90","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11899-020-00567-4","article-title":"The Cardiovascular Complications of Chimeric Antigen Receptor T Cell Therapy","volume":"15","author":"Jamal","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"6","key":"10.1016\/j.phrs.2026.108316_bib91","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2026.108316_bib92","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbi.2018.09.027","article-title":"Molecular hydrogen potentiates hypothermia and prevents hypotension and fever in LPS-induced systemic inflammation","volume":"75","author":"Saramago","year":"2019","journal-title":"Brain Behav. Immun."},{"issue":"17","key":"10.1016\/j.phrs.2026.108316_bib93","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.phrs.2026.108316_bib94","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.37222","article-title":"Cardiovascular Events After Chimeric Antigen Receptor T-Cell Therapy for Advanced Hematologic Malignant Neoplasms: A Meta-Analysis","volume":"7","author":"Koeckerling","year":"2024","journal-title":"JAMA Netw. Open."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib95","first-page":"18","article-title":"Inflammation and acute cardiotoxicity in adult hematological patients treated with CAR-T cells: results from a pilot proof-of-concept study","volume":"10","author":"Camilli","year":"2024","journal-title":"Cardiooncology"},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib96","doi-asserted-by":"crossref","first-page":"113","DOI":"10.36401\/JIPO-20-10","article-title":"Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias","volume":"3","author":"Simbaqueba","year":"2020","journal-title":"J. Immunother. Precis. Oncol."},{"issue":"22","key":"10.1016\/j.phrs.2026.108316_bib97","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1161\/CIRCULATIONAHA.104.475194","article-title":"Jr., Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation","volume":"111","author":"Ishii","year":"2005","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.phrs.2026.108316_bib98","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1136\/heartjnl-2016-311079","article-title":"Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes","volume":"103","author":"Lazzerini","year":"2017","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib99","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am. J. Kidney Dis."},{"issue":"10","key":"10.1016\/j.phrs.2026.108316_bib100","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/ejhf.3340","article-title":"Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology","volume":"26","author":"Tocchetti","year":"2024","journal-title":"Eur. J. Heart Fail."},{"issue":"9","key":"10.1016\/j.phrs.2026.108316_bib101","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00134-024-07576-4","article-title":"Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities","volume":"50","author":"Schroeder","year":"2024","journal-title":"Intensive Care Med."},{"issue":"4","key":"10.1016\/j.phrs.2026.108316_bib102","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.phrs.2026.108316_bib103","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.phrs.2026.108316_bib104","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.mayocp.2022.05.018","article-title":"Incidence and Risk Factors for Acute Kidney Injury After Chimeric Antigen Receptor T-Cell Therapy","volume":"97","author":"Farooqui","year":"2022","journal-title":"Mayo Clin. Proc."},{"issue":"6","key":"10.1016\/j.phrs.2026.108316_bib105","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40264-025-01635-5","article-title":"Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert Consensus","volume":"49","author":"Fettiplace","year":"2026","journal-title":"Drug. Saf."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib106","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","article-title":"DLL3: an emerging target in small cell lung cancer","volume":"12","author":"Owen","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"22","key":"10.1016\/j.phrs.2026.108316_bib107","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.phrs.2026.108316_bib108","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014","article-title":"Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer","volume":"4","author":"Ganatra","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib109","first-page":"18","article-title":"Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study","volume":"9","author":"Lee","year":"2023","journal-title":"Cardiooncology"},{"issue":"4","key":"10.1016\/j.phrs.2026.108316_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061338","article-title":"CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia","volume":"8","author":"Davila","year":"2013","journal-title":"PLoS. One"},{"issue":"12","key":"10.1016\/j.phrs.2026.108316_bib111","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.4049\/jimmunol.1103019","article-title":"Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-gamma and GM-CSF","volume":"188","author":"Spear","year":"2012","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib112","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.fmre.2023.05.016","article-title":"A tetramethylpyrazine releasing hydrogel can potentiate CAR-T cell therapy against triple negative breast cancer by reprogramming tumor vasculatures","volume":"5","author":"Liu","year":"2025","journal-title":"Fundam. Res."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib113","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1172\/JCI117713","article-title":"The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta","volume":"95","author":"Pinsky","year":"1995","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.phrs.2026.108316_bib114","article-title":"A major role for CD4(+) T cells in driving cytokine release syndrome during CAR T cell therapy","volume":"4","author":"Boulch","year":"2023","journal-title":"Cell. Rep. Med."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib115","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or Deletion of IFNgamma Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov."},{"issue":"3-4","key":"10.1016\/j.phrs.2026.108316_bib116","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s10495-023-01925-2","article-title":"A novel safer CD19CAR with shRNA interference of IFN-gamma can reduce multiple cytokine levels without significantly compromising its killing efficacy","volume":"29","author":"Zhang","year":"2024","journal-title":"Apoptosis"},{"issue":"43","key":"10.1016\/j.phrs.2026.108316_bib117","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aax7969","article-title":"Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome","volume":"5","author":"Liu","year":"2020","journal-title":"Sci. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib118","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib119","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","article-title":"DAMP-sensing receptors in sterile inflammation and inflammatory diseases","volume":"20","author":"Gong","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib120","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001466","article-title":"Blockade of AIM2 inflammasome or alpha1-AR ameliorates IL-1beta release and macrophage-mediated immunosuppression induced by CAR-T treatment","volume":"9","author":"Liu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.phrs.2026.108316_bib121","article-title":"Cornus officinalis total glycosides modulate inflammatory response and inhibit the JAK1\/STAT3 pathway within a preclinical rat model of cardiac ischemia\/reperfusion-induced injury","volume":"139","author":"Chen","year":"2025","journal-title":"Cell. Signal."},{"issue":"8","key":"10.1016\/j.phrs.2026.108316_bib122","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/labinvest.2016.65","article-title":"Hypoxia-stimulated cardiac fibroblast production of IL-6 promotes myocardial fibrosis via the TGF-beta1 signaling pathway","volume":"96","author":"Wang","year":"2016","journal-title":"Lab. Invest."},{"issue":"5","key":"10.1016\/j.phrs.2026.108316_bib123","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cvr\/cvy013","article-title":"T.S. Group, IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis","volume":"114","author":"Chou","year":"2018","journal-title":"Cardiovasc. Res."},{"issue":"6","key":"10.1016\/j.phrs.2026.108316_bib124","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004400","article-title":"PD-L1 blockade restores CAR T cell activity through IFN-gamma-regulation of CD163+ M2 macrophages","volume":"10","author":"Yamaguchi","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.phrs.2026.108316_bib125","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1002\/eji.1830241235","article-title":"Role of the CD40-CD40 ligand interaction in CD4+ T cell contact-dependent activation of monocyte interleukin-1 synthesis","volume":"24","author":"Wagner","year":"1994","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108316_bib126","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.4049\/jimmunol.162.5.2748","article-title":"Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells","volume":"162","author":"Avice","year":"1999","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.phrs.2026.108316_bib127","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.4049\/jimmunol.158.8.3673","article-title":"Contact with T cells modulates monocyte IL-10 production: role of T cell membrane TNF-alpha","volume":"158","author":"Parry","year":"1997","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108316_bib128","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.phrs.2026.108316_bib129","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/2159-8290.CD-20-1661","article-title":"IFNgamma Is Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous Immunity","volume":"11","author":"Alizadeh","year":"2021","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.phrs.2026.108316_bib130","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"17","key":"10.1016\/j.phrs.2026.108316_bib131","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2026.108316_bib132","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.yjmcc.2014.08.022","article-title":"Exendin-4 improves cardiac function in mice overexpressing monocyte chemoattractant protein-1 in cardiomyocytes","volume":"76","author":"Younce","year":"2014","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108316_bib133","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1161\/CIRCULATIONAHA.106.646091","article-title":"Critical role of monocyte chemoattractant protein-1\/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy","volume":"115","author":"Frangogiannis","year":"2007","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib134","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12964-018-0268-4","article-title":"Activation of the JAK\/STAT3 and PI3K\/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells","volume":"16","author":"Zegeye","year":"2018","journal-title":"Cell. Commun. Signal."},{"issue":"5","key":"10.1016\/j.phrs.2026.108316_bib135","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1172\/JCI133661","article-title":"Local microvascular leakage promotes trafficking of activated neutrophils to remote organs","volume":"130","author":"Owen-Woods","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.phrs.2026.108316_bib136","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.70107","article-title":"Neohesperidin Dihydrochalcone Alleviates Lipopolysaccharide-Induced Vascular Endothelium Dysfunction by Regulating Antioxidant Capacity","volume":"12","author":"Nong","year":"2024","journal-title":"Immun. Inflamm. Dis."},{"issue":"8","key":"10.1016\/j.phrs.2026.108316_bib137","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/2326-6066.CIR-24-0876","article-title":"Secretion of a VEGF-Blocking scFv Enhances CAR T-cell Potency","volume":"13","author":"Supper","year":"2025","journal-title":"Cancer Immunol. Res."},{"issue":"9","key":"10.1016\/j.phrs.2026.108316_bib138","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1161\/CIRCRESAHA.116.310477","article-title":"VEGFR3 Modulates Vascular Permeability by Controlling VEGF\/VEGFR2 Signaling","volume":"120","author":"Heinolainen","year":"2017","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib139","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12933-023-01941-1","article-title":"Endothelial MICU1 alleviates diabetic cardiomyopathy by attenuating nitrative stress-mediated cardiac microvascular injury","volume":"22","author":"Shi","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"issue":"8","key":"10.1016\/j.phrs.2026.108316_bib140","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.2337\/dc11-0476","article-title":"M.L. Caramori, g. Renin Angiotensin System Study, Benefits of Renin-Angiotensin blockade on retinopathy in type 1 diabetes vary with glycemic control","volume":"34","author":"Harindhanavudhi","year":"2011","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib141","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/jcmm.13958","article-title":"Cardiac-specific Mst1 deficiency inhibits ROS-mediated JNK signalling to alleviate Ang II-induced cardiomyocyte apoptosis","volume":"23","author":"Cheng","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.phrs.2026.108316_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2024.102627","article-title":"C1q\/tumor necrosis factor-related protein-6 suppresses the angiotensin II-induced differentiation of cardiac fibroblasts to myofibroblasts via activation of the AMPK pathway","volume":"91","author":"Wu","year":"2024","journal-title":"Tissue Cell."},{"issue":"5","key":"10.1016\/j.phrs.2026.108316_bib143","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1161\/01.RES.0000118250.67032.5E","article-title":"Calcineurin promotes the expression of monocyte chemoattractant protein-1 in vascular myocytes and mediates vascular inflammation","volume":"94","author":"Satonaka","year":"2004","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib144","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl. Infect. Dis."},{"issue":"8","key":"10.1016\/j.phrs.2026.108316_bib145","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.phrs.2026.108316_bib146","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1021\/acsinfecdis.4c00319","article-title":"GPR30 Agonist G1 Mitigates Sepsis-Induced Cardiac Dysfunction by Inhibiting ACE2\/c-FOS-Mediated Necroptosis in Female Mice","volume":"10","author":"Wang","year":"2024","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.phrs.2026.108316_bib147","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/978-3-031-59815-9_37","article-title":"IL-6 Blockade in Cytokine Storm Syndromes","volume":"1448","author":"Barrett","year":"2024","journal-title":"Adv. Exp. Med. Biol."},{"issue":"17","key":"10.1016\/j.phrs.2026.108316_bib148","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial","volume":"38","author":"Shah","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.phrs.2026.108316_bib149","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2026.108316_bib150","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fimmu.2020.00524","volume":"11","author":"Sandler","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib151","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/s41467-021-21737-9","article-title":"Cytotoxic CD8(+) T cells promote granzyme B-dependent adverse post-ischemic cardiac remodeling","volume":"12","author":"Santos-Zas","year":"2021","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.phrs.2026.108316_bib152","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s13312-020-1962-z","article-title":"COVID-19 Associated Hemophagocytic Lymphohistiocytosis and Coagulopathy: Targeting the Duumvirate","volume":"57","author":"Bhattacharjee","year":"2020","journal-title":"Indian. Pediatr."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib153","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12885-021-09102-x","article-title":"Hu, Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis","volume":"22","author":"Luo","year":"2022","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2026.108316_bib154","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","article-title":"Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes","volume":"181","author":"Brocker","year":"1995","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib155","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ymthe.2020.10.008","article-title":"Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7","volume":"29","author":"Amatya","year":"2021","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib156","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib157","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1186\/s12967-025-06608-x","article-title":"Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial","volume":"23","author":"He","year":"2025","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib158","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41467-020-20599-x","article-title":"Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma","volume":"12","author":"Agliardi","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib159","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/d41573-021-00034-6","article-title":"Restoring IL-2 to its cancer immunotherapy glory","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"11","key":"10.1016\/j.phrs.2026.108316_bib160","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"625","key":"10.1016\/j.phrs.2026.108316_bib161","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A human orthogonal IL-2 and IL-2Rbeta system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.phrs.2026.108316_bib162","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/s41417-024-00823-2","article-title":"FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma","volume":"31","author":"Xiao","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"8","key":"10.1016\/j.phrs.2026.108316_bib163","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib164","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit. Care Med."},{"issue":"4","key":"10.1016\/j.phrs.2026.108316_bib165","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib166","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41409-022-01888-z","article-title":"Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed\/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trial","volume":"58","author":"Ying","year":"2023","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib167","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","article-title":"Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL","volume":"4","author":"Awasthi","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.phrs.2026.108316_bib168","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.848091","article-title":"Case Report: Cardiac Tamponade in Association With Cytokine Release Syndrome Following CAR-T Cell Therapy","volume":"9","author":"Moriyama","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.phrs.2026.108316_bib169","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/TCRM.S150524","article-title":"Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy","volume":"15","author":"Riegler","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib170","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib171","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40164-021-00209-2","article-title":"Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy","volume":"10","author":"Zhang","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108316_bib172","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.phrs.2026.108316_bib173","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/bloodadvances.2024015161","article-title":"Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma","volume":"9","author":"Frigault","year":"2025","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib174","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jcmm.16176","article-title":"Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy","volume":"25","author":"Pan","year":"2021","journal-title":"J. Cell. Mol. Med."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib175","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/10428194.2022.2148209","article-title":"Successful treatment of severe cytokine release syndrome after CAR-T therapy by ruxolitinib without compromising CAR-T efficacy","volume":"64","author":"Gu","year":"2023","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib176","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jtct.2025.09.028","article-title":"Management Practices of CAR T-cell-Related Inflammatory Toxicities: A Survey of Pediatric CAR T-cell Providers","volume":"32","author":"McNerney","year":"2026","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.phrs.2026.108316_bib177","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1543622","article-title":"Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report","volume":"15","author":"Ruemmele","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2026.108316_bib178","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1563736","article-title":"Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy","volume":"16","author":"Manghisi","year":"2025","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib179","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2643-3230.BCD-21-0203","article-title":"Potential Role of IFNgamma Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy","volume":"3","author":"McNerney","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.phrs.2026.108316_bib180","article-title":"Emapalumab in pediatric patients with high-grade cytokine release syndrome associated with CAR T-cell therapy","volume":"17","author":"Zhang","year":"2026","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib181","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3892\/ol.2024.14817","article-title":"Efficacy of emapalumab in the management of anti-CD19 chimeric antigen receptor T-cell therapy-associated cytokine release syndrome: A report of two cases","volume":"29","author":"Cai","year":"2025","journal-title":"Oncol. Lett."},{"issue":"8","key":"10.1016\/j.phrs.2026.108316_bib182","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","article-title":"Off-the-shelf, steroid-resistant, IL13Ralpha2-specific CAR T cells for treatment of glioblastoma","volume":"24","author":"Brown","year":"2022","journal-title":"Neuro Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108316_bib183","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41591-026-04244-6","article-title":"vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study","volume":"32","author":"An","year":"2026","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.phrs.2026.108316_bib184","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230577","article-title":"IL-6 translation is a therapeutic target of human cytokine release syndrome","volume":"220","author":"Yang","year":"2023","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib185","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.phrs.2026.108316_bib186","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.bbmt.2018.05.014","article-title":"Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience","volume":"24","author":"Burstein","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib187","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib188","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1158\/1078-0432.CCR-18-1379","article-title":"Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report","volume":"25","author":"Xiao","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.phrs.2026.108316_bib189","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/CJI.0000000000000243","article-title":"Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy","volume":"41","author":"Liu","year":"2018","journal-title":"J. Immunother."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib190","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1038\/s41467-023-38723-y","article-title":"Neutralizing IFNgamma improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies","volume":"14","author":"Manni","year":"2023","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.phrs.2026.108316_bib191","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1111\/jcmm.14972","article-title":"Aminooxyacetic acid attenuates post-infarct cardiac dysfunction by balancing macrophage polarization through modulating macrophage metabolism in mice","volume":"24","author":"Zhao","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.phrs.2026.108316_bib192","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jconrel.2016.12.042","article-title":"Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction","volume":"247","author":"Allijn","year":"2017","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib193","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1080\/13880209.2020.1840597","article-title":"Latifolin protects against myocardial infarction by alleviating myocardial inflammatory via the HIF-1alpha\/NF-kappaB\/IL-6 pathway","volume":"58","author":"Lai","year":"2020","journal-title":"Pharm. Biol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib194","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/cvr\/cvv224","article-title":"BLT1 antagonist LSN2792613 reduces infarct size in a mouse model of myocardial ischaemia-reperfusion injury","volume":"108","author":"de Hoog","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.phrs.2026.108316_bib195","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110384","article-title":"Colchicine prevents atrial fibrillation promotion by inhibiting IL-1beta-induced IL-6 release and atrial fibrosis in the rat sterile pericarditis model","volume":"129","author":"Wu","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2026.108316_bib196","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114732","article-title":"Colchicine inhibits myocardial pyroptosis and reduces myocardial cell injury after myocardial infarction through the ESR1-PI3K-Akt-NF-kappaB signaling pathway","volume":"156","author":"Chen","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.phrs.2026.108316_bib197","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.yjmcc.2021.05.008","article-title":"Dimethyl fumarate preserves left ventricular infarct integrity following myocardial infarction via modulation of cardiac macrophage and fibroblast oxidative metabolism","volume":"158","author":"Mouton","year":"2021","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.phrs.2026.108316_bib198","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106652","article-title":"Ginkgolide B attenuates myocardial infarction-induced depression-like behaviors via repressing IL-1beta in central nervous system","volume":"85","author":"Ge","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108316_bib199","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2025.5498","article-title":"Remimazolam alleviates myocardial ischemia\/reperfusion injury and inflammation via inhibition of the NLRP3\/IL-1beta pathway in mice","volume":"55","author":"Liu","year":"2025","journal-title":"Int. J. Mol. Med."},{"issue":"5","key":"10.1016\/j.phrs.2026.108316_bib200","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00395-018-0692-z","article-title":"Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y(12) receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function","volume":"113","author":"Audia","year":"2018","journal-title":"Basic. Res. Cardiol."},{"key":"10.1016\/j.phrs.2026.108316_bib201","doi-asserted-by":"crossref","DOI":"10.1155\/cdr\/5289405","article-title":"Aldehyde Dehydrogenase-2 Alleviates Septic Myocardial Injury by Inhibiting Caspase-11-Mediated Noncanonical Pyroptosis","volume":"2026","author":"Liang","year":"2026","journal-title":"Cardiovasc. Ther."},{"issue":"9","key":"10.1016\/j.phrs.2026.108316_bib202","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.intimp.2009.04.010","article-title":"Amlodipine inhibits TNF-alpha production and attenuates cardiac dysfunction induced by lipopolysaccharide involving PI3K\/Akt pathway","volume":"9","author":"Li","year":"2009","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib203","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1124\/jpet.103.054700","article-title":"The aminotetraline derivative (+\/-)-(R,S)-5,6-dihydroxy-2-methylamino-1,2,3,4-tetrahydro-naphthalene hydrochloride (CHF-1024) displays cardioprotection in postischemic ventricular dysfunction of the rat heart","volume":"307","author":"Rossoni","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"12","key":"10.1016\/j.phrs.2026.108316_bib204","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.phymed.2016.07.015","article-title":"Kampeferol protects against oxidative stress and apoptotic damage in experimental model of isoproterenol-induced cardiac toxicity in rats","volume":"23","author":"Suchal","year":"2016","journal-title":"Phytomedicine"},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058371","article-title":"alpha-Lipoic acid reduces infarct size and preserves cardiac function in rat myocardial ischemia\/reperfusion injury through activation of PI3K\/Akt\/Nrf2 pathway","volume":"8","author":"Deng","year":"2013","journal-title":"PLoS. One"},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib206","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12012-016-9358-y","article-title":"17-Methoxyl-7-Hydroxy-Benzene-Furanchalcone Ameliorates Myocardial Ischemia\/Reperfusion Injury in Rat by Inhibiting Apoptosis and Autophagy Via the PI3K-Akt Signal Pathway","volume":"17","author":"Xuan","year":"2017","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.phrs.2026.108316_bib207","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.intimp.2017.04.002","article-title":"Metformin attenuated endotoxin-induced acute myocarditis via activating AMPK","volume":"47","author":"Liu","year":"2017","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108316_bib208","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1023\/B:CARD.0000041247.95545.55","article-title":"3,4,5,6-Tetrahydroxyxanthone protects against myocardial ischemia-reperfusion injury in rats","volume":"18","author":"Dai","year":"2004","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"5","key":"10.1016\/j.phrs.2026.108316_bib209","article-title":"Yohimbine promotes cardiac NE release and prevents LPS-induced cardiac dysfunction via blockade of presynaptic alpha2A-adrenergic receptor","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS. One"},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib210","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jep.2011.12.001","article-title":"2-methoxycinnamaldehyde from Cinnamomum cassia reduces rat myocardial ischemia and reperfusion injury in vivo due to HO-1 induction","volume":"139","author":"Hwa","year":"2012","journal-title":"J. Ethnopharmacol."},{"issue":"37","key":"10.1016\/j.phrs.2026.108316_bib211","article-title":"Cytokine Storm Induction Linked to Multi-Organ Failure in Fatal Jellyfish Stings","volume":"12","author":"Wang","year":"2025","journal-title":"Adv. Sci. (Weinh. )"},{"key":"10.1016\/j.phrs.2026.108316_bib212","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.ijbiomac.2019.10.227","article-title":"Protective effects of astragalus polysaccharide nanoparticles on septic cardiac dysfunction through inhibition of TLR4\/NF-kappaB signaling pathway","volume":"153","author":"Xu","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.phrs.2026.108316_bib213","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.131800","article-title":"Aucubin protects against myocardial ischemia-reperfusion injury by regulating STAT3\/NF-kappaB\/HMGB-1 pathway","volume":"400","author":"Liu","year":"2024","journal-title":"Int. J. Cardiol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108316_bib214","doi-asserted-by":"crossref","DOI":"10.1590\/s0102-865020190110000004","article-title":"Biochanin A attenuates myocardial ischemia\/reperfusion injury through the TLR4\/NF-kappaB\/NLRP3 signaling pathway","volume":"34","author":"Bai","year":"2019","journal-title":"Acta Cir. Bras."},{"issue":"6","key":"10.1016\/j.phrs.2026.108316_bib215","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.pharep.2019.06.015","article-title":"A novel isoquinoline derivative exhibits anti-inflammatory properties and improves the outcomes of endotoxemia","volume":"71","author":"Lee","year":"2019","journal-title":"Pharmacol. Rep."},{"issue":"7-8","key":"10.1016\/j.phrs.2026.108316_bib216","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.lfs.2008.12.005","article-title":"Daidzein administration in vivo reduces myocardial injury in a rat ischemia\/reperfusion model by inhibiting NF-kappaB activation","volume":"84","author":"Kim","year":"2009","journal-title":"Life Sci."},{"issue":"7-8","key":"10.1016\/j.phrs.2026.108316_bib217","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1159\/000513631","article-title":"Daphnetin Preconditioning Decreases Cardiac Injury and Susceptibility to Ventricular Arrhythmia following Ischaemia-Reperfusion through the TLR4\/MyD88\/NF-Kappab Signalling Pathway","volume":"106","author":"Yang","year":"2021","journal-title":"Pharmacology"},{"key":"10.1016\/j.phrs.2026.108316_bib218","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.118612","article-title":"Ecliptasaponin A protects heart against acute ischemia-induced myocardial injury by inhibition of the HMGB1\/TLR4\/NF-kappaB pathway","volume":"335","author":"Ge","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.phrs.2026.108316_bib219","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111897","article-title":"Esculin targets TLR4 to protect against LPS-induced septic cardiomyopathy","volume":"131","author":"Su","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.phrs.2026.108316_bib220","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.3389\/fimmu.2018.02844","article-title":"Cardioprotection of Ginkgolide B on Myocardial Ischemia\/Reperfusion-Induced Inflammatory Injury via Regulation of A20-NF-kappaB Pathway","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108316_bib221","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.biopha.2016.03.032","article-title":"Paeoniflorin attenuates cardiac dysfunction in endotoxemic mice via the inhibition of nuclear factor-kappaB","volume":"80","author":"Zhai","year":"2016","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib222","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.intimp.2010.11.012","article-title":"Paeoniflorin improves survival in LPS-challenged mice through the suppression of TNF-alpha and IL-1beta release and augmentation of IL-10 production","volume":"11","author":"Cao","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.phrs.2026.108316_bib223","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173524","article-title":"The protective effect of piperine against isoproterenol-induced inflammation in experimental models of myocardial toxicity","volume":"885","author":"Viswanadha","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108316_bib224","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2025.123896","article-title":"Cardioprotective role of phoenixin-14 in isoproterenol-induced myocardial injury: Involvement of AMPK, JAK2\/STAT3, and Sema3E pathways","volume":"379","author":"Akcilar","year":"2025","journal-title":"Life Sci."},{"issue":"12","key":"10.1016\/j.phrs.2026.108316_bib225","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23123322","article-title":"Cardioprotective Effects of Puerarin-V on Isoproterenol-Induced Myocardial Infarction Mice Is Associated with Regulation of PPAR-Upsilon\/NF-kappaB Pathway","volume":"23","author":"Li","year":"2018","journal-title":"Molecules"},{"issue":"Pt A","key":"10.1016\/j.phrs.2026.108316_bib226","article-title":"Maresin1 ameliorates ventricular remodelling and arrhythmia in mice models of myocardial infarction via NRF2\/HO-1 and TLR4\/NF-kB signalling","volume":"113","author":"Wang","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib227","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1139\/cjpp-2015-0073","article-title":"Mangiferin suppressed advanced glycation end products (AGEs) through NF-kappaB deactivation and displayed anti-inflammatory effects in streptozotocin and high fat diet-diabetic cardiomyopathy rats","volume":"94","author":"Hou","year":"2016","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108316_bib228","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10557-019-06884-y","article-title":"Resolvin D1 Attenuates Myocardial Infarction in a Rodent Model with the Participation of the HMGB1 Pathway","volume":"33","author":"Liu","year":"2019","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib229","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12906-023-04081-x","article-title":"Cardioprotective effects of Schisantherin A against isoproterenol-induced acute myocardial infarction through amelioration of oxidative stress and inflammation via modulation of PI3K-AKT\/Nrf2\/ARE and TLR4\/MAPK\/NF-kappaB pathways in rats","volume":"23","author":"Mi","year":"2023","journal-title":"BMC Complement. Med. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib230","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jep.2011.03.052","article-title":"Sophocarpine administration preserves myocardial function from ischemia-reperfusion in rats via NF-kappaB inactivation","volume":"135","author":"Li","year":"2011","journal-title":"J. Ethnopharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib231","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s10753-019-01158-z","article-title":"Isofraxidin Alleviates Myocardial Infarction Through NLRP3 Inflammasome Inhibition","volume":"43","author":"Chen","year":"2020","journal-title":"Inflammation"},{"issue":"12","key":"10.1016\/j.phrs.2026.108316_bib232","first-page":"4235","article-title":"Muscone improves cardiac function in mice after myocardial infarction by alleviating cardiac macrophage-mediated chronic inflammation through inhibition of NF-kappaB and NLRP3 inflammasome","volume":"10","author":"Du","year":"2018","journal-title":"Am. J. Transl. Res."},{"issue":"11","key":"10.1016\/j.phrs.2026.108316_bib233","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23458","article-title":"Muscone attenuates susceptibility to ventricular arrhythmia by inhibiting NLRP3 inflammasome activation in rats after myocardial infarction","volume":"37","author":"Yang","year":"2023","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.phrs.2026.108316_bib234","article-title":"Phloretin ameliorates heart function after myocardial infarction via NLRP3\/Caspase-1\/IL-1beta signaling","volume":"165","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib235","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/ptr.8024","article-title":"Phenolic acids from Prunella vulgaris alleviate cardiac remodeling following myocardial infarction partially by suppressing NLRP3 activation","volume":"38","author":"Wei","year":"2024","journal-title":"Phytother. Res."},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib236","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2021.12315","article-title":"Sacubitril\/valsartan (LCZ696) reduces myocardial injury following myocardial infarction by inhibiting NLRP3-induced pyroptosis via the TAK1\/JNK signaling pathway","volume":"24","author":"Shen","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.phrs.2026.108316_bib237","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.04.022","article-title":"The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction","volume":"74","author":"Gao","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.phrs.2026.108316_bib238","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2021.114841","article-title":"Qishen granule (QSG) exerts cardioprotective effects by inhibiting NLRP3 inflammasome and pyroptosis in myocardial infarction rats","volume":"285","author":"Chen","year":"2022","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.phrs.2026.108316_bib239","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2025.119563","article-title":"The stems of Syringa oblata Lindl. exert cardioprotective effects against acute myocardial ischemia by inhibiting the TLR4\/MyD88\/NF-kappaB and NLRP3 inflammasome signaling pathways in mice","volume":"344","author":"Xu","year":"2025","journal-title":"J. Ethnopharmacol."},{"issue":"8","key":"10.1016\/j.phrs.2026.108316_bib240","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23773","article-title":"Protective effects of 3, 4-dihydroxybenzoic acid on myocardial infarction induced by isoproterenol in rats","volume":"38","author":"Vincent","year":"2024","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.phrs.2026.108316_bib241","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.yjmcc.2021.05.014","article-title":"5-Methoxytryptophan attenuates postinfarct cardiac injury by controlling oxidative stress and immune activation","volume":"158","author":"Hsu","year":"2021","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.phrs.2026.108316_bib242","doi-asserted-by":"crossref","first-page":"36435","DOI":"10.1038\/srep36435","article-title":"Water-soluble acacetin prodrug confers significant cardioprotection against ischemia\/reperfusion injury","volume":"6","author":"Liu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2026.108316_bib243","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113825","article-title":"Atractylenolide-III restrains cardiac fibrosis after myocardial infarction via suppression of the RhoA\/ROCK1 and ERK1\/2 pathway","volume":"145","author":"Li","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108316_bib244","doi-asserted-by":"crossref","DOI":"10.1152\/ajpheart.01106.2004","article-title":"Caffeic acid phenethyl ester possesses potent cardioprotective effects in a rabbit model of acute myocardial ischemia-reperfusion injury","volume":"289","author":"Tan","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib245","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/FJC.0000000000000710","article-title":"Carthamin Yellow Protects the Heart Against Ischemia\/Reperfusion Injury With Reduced Reactive Oxygen Species Release and Inflammatory Response","volume":"74","author":"Lu","year":"2019","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"12","key":"10.1016\/j.phrs.2026.108316_bib246","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1159\/000517185","article-title":"Celastrol Exerts Cardioprotective Effect in Rheumatoid Arthritis by Inhibiting TLR2\/HMGB1 Signaling Pathway-Mediated Autophagy","volume":"182","author":"Lu","year":"2021","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.phrs.2026.108316_bib247","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jep.2017.06.020","article-title":"Corydalis hendersonii Hemsl. protects against myocardial injury by attenuating inflammation and fibrosis via NF-kappaB and JAK2-STAT3 signaling pathways","volume":"207","author":"Bai","year":"2017","journal-title":"J. Ethnopharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib248","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24020270","article-title":"Clofibrate Treatment Decreases Inflammation and Reverses Myocardial Infarction-Induced Remodelation in a Rodent Experimental Model","volume":"24","author":"Ibarra-Lara","year":"2019","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib249","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.atherosclerosis.2013.10.003","article-title":"Coptisine protects rat heart against myocardial ischemia\/reperfusion injury by suppressing myocardial apoptosis and inflammation","volume":"231","author":"Guo","year":"2013","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib250","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2022.12907","article-title":"Crocin inhibits KBTBD7 to prevent excessive inflammation and cardiac dysfunction following myocardial infarction","volume":"27","author":"Yuan","year":"2023","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.phrs.2026.108316_bib251","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2025.111618","article-title":"Dichloroacetate: A metabolic game-changer in alleviating macrophage inflammation and enhancing recovery after myocardial infarction","volume":"127","author":"Lv","year":"2025","journal-title":"Cell. Signal."},{"issue":"7","key":"10.1016\/j.phrs.2026.108316_bib252","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218726","article-title":"Dexmedetomidine-induced cardioprotection is mediated by inhibition of high mobility group box-1 and the cholinergic anti-inflammatory pathway in myocardial ischemia-reperfusion injury","volume":"14","author":"Zhang","year":"2019","journal-title":"PLoS. One"},{"issue":"5","key":"10.1016\/j.phrs.2026.108316_bib253","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/cbdd.14324","article-title":"Dexmedetomidine attenuates myocardial ischemia-reperfusion injury in hyperlipidemic rats by inhibiting inflammation, oxidative stress and NF-kappaB","volume":"102","author":"Gao","year":"2023","journal-title":"Chem. Biol. Drug. Des."},{"issue":"7","key":"10.1016\/j.phrs.2026.108316_bib254","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.1399-6576.2007.01363.x","article-title":"The beta-adrenoceptor antagonist propranolol counteracts anti-inflammatory effects of isoflurane in rat endotoxemia","volume":"51","author":"Boost","year":"2007","journal-title":"Acta Anaesthesiol. Scand."},{"issue":"6","key":"10.1016\/j.phrs.2026.108316_bib255","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1186\/s13054-014-0610-1","article-title":"Effects of selective beta1-adrenoceptor blockade on cardiovascular and renal function and circulating cytokines in ovine hyperdynamic sepsis","volume":"18","author":"Calzavacca","year":"2014","journal-title":"Crit. Care"},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib256","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s13105-014-0320-9","article-title":"Diosgenin attenuates inflammatory response induced by myocardial reperfusion injury: role of mitochondrial ATP-sensitive potassium channels","volume":"70","author":"Ebrahimi","year":"2014","journal-title":"J. Physiol. Biochem."},{"key":"10.1016\/j.phrs.2026.108316_bib257","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12872-016-0294-3","article-title":"Cardioprotection provided by Echinatin against ischemia\/reperfusion in isolated rat hearts","volume":"16","author":"Tian","year":"2016","journal-title":"BMC Cardiovasc. Disord."},{"issue":"7","key":"10.1016\/j.phrs.2026.108316_bib258","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.injury.2009.12.006","article-title":"Erythropoietin protects severe haemorrhagic shock-induced organ damage in conscious rats","volume":"41","author":"Wu","year":"2010","journal-title":"Injury"},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib259","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12012-021-09698-3","article-title":"Vivo and In Vitro Cardioprotective Effect of Gossypin Against Isoproterenol-Induced Myocardial Infarction Injury","volume":"22","author":"Cinar","year":"2022","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.phrs.2026.108316_bib260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175478","article-title":"Administration of Huperzine A microspheres ameliorates myocardial ischemic injury via alpha7nAChR-dependent JAK2\/STAT3 signaling pathway","volume":"940","author":"Zhang","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108316_bib261","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2023.110745","article-title":"Punicalagin attenuates myocardial oxidative damage, inflammation, and apoptosis in isoproterenol-induced myocardial infarction in rats: Biochemical, immunohistochemical, and in silico molecular docking studies","volume":"385","author":"Jghef","year":"2023","journal-title":"Chem. Biol. Interact."},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib262","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2021.4862","article-title":"Resveratrol protects against myocardial ischemic injury via the inhibition of NF-kappaB-dependent inflammation and the enhancement of antioxidant defenses","volume":"47","author":"He","year":"2021","journal-title":"Int. J. Mol. Med."},{"issue":"20","key":"10.1016\/j.phrs.2026.108316_bib263","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262010073","article-title":"Alpinetin Alleviates Cardiac Inflammation and Remodeling via TLR4\/MyD88\/NF-kappaB Signaling Pathway in Rats with Acute Myocardial Infarction","volume":"26","author":"Feng","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.phrs.2026.108316_bib264","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26175137","article-title":"Cardioprotective Potential of Garlic Oil and Its Active Constituent, Diallyl Disulphide, in Presence of Carvedilol during Chronic Isoprenaline Injection-Mediated Myocardial Necrosis in Rats","volume":"26","author":"Asdaq","year":"2021","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.phrs.2026.108316_bib265","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.peptides.2009.09.004","article-title":"Ghrelin inhibits post-infarct myocardial remodeling and improves cardiac function through anti-inflammation effect","volume":"30","author":"Huang","year":"2009","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2026.108316_bib266","doi-asserted-by":"crossref","first-page":"35319","DOI":"10.1038\/srep35319","article-title":"Hydroxysafflor yellow A alleviates myocardial ischemia\/reperfusion in hyperlipidemic animals through the suppression of TLR4 signaling","volume":"6","author":"Han","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib267","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3892\/mmr.2014.2676","article-title":"Lycopene attenuates inflammation and apoptosis in post-myocardial infarction remodeling by inhibiting the nuclear factor-kappaB signaling pathway","volume":"11","author":"He","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.phrs.2026.108316_bib268","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ijcard.2016.07.250","article-title":"Methanolic seed extract of Vitis vinifera ameliorates oxidative stress, inflammation and ATPase dysfunction in infarcted and non-infarcted heart of streptozotocin-nicotinamide induced male diabetic rats","volume":"222","author":"Giribabu","year":"2016","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib269","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12012-014-9271-1","article-title":"Oleuropein offers cardioprotection in rats with acute myocardial infarction","volume":"15","author":"Janahmadi","year":"2015","journal-title":"Cardiovasc. Toxicol."},{"issue":"12","key":"10.1016\/j.phrs.2026.108316_bib270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138051","article-title":"Penehyclidine Hydrochloride Preconditioning Provides Cardioprotection in a Rat Model of Myocardial Ischemia\/Reperfusion Injury","volume":"10","author":"Lin","year":"2015","journal-title":"PLoS. One"},{"key":"10.1016\/j.phrs.2026.108316_bib271","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.intimp.2017.11.015","article-title":"Propofol attenuates myocardial ischemia reperfusion injury partly through inhibition of resident cardiac mast cell activation","volume":"54","author":"Yu","year":"2018","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108316_bib272","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/bab.1797","article-title":"Vitamin D attenuates myocardial ischemia-reperfusion injury by inhibiting inflammation via suppressing the RhoA\/ROCK\/NF-kB pathway","volume":"66","author":"Qian","year":"2019","journal-title":"Biotechnol. Appl. Biochem."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib273","article-title":"Protective effects of Salidroside on cardiac function in mice with myocardial infarction","volume":"9","author":"Chen","year":"2019","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.phrs.2026.108316_bib274","doi-asserted-by":"crossref","first-page":"H1760","DOI":"10.1152\/ajpheart.00735.2015","article-title":"The contributions of dipeptidyl peptidase IV to inflammation in heart failure","volume":"310","author":"de Almeida Salles","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.phrs.2026.108316_bib275","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1538697","article-title":"Scutellarin ameliorates ischemia\/reperfusion-mediated endothelial dysfunction by upregulating cathepsin D expression to rescue autophagy-lysosomal function","volume":"16","author":"Zhuang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108316_bib276","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174644","article-title":"Syringaresinol attenuates sepsis-induced cardiac dysfunction by inhibiting inflammation and pyroptosis in mice","volume":"913","author":"Wei","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib277","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.intimp.2015.07.004","article-title":"Tanshinone IIA attenuates cardiac dysfunction in endotoxin-induced septic mice via inhibition of NADPH oxidase 2-related signaling pathway","volume":"28","author":"Huang","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.phrs.2026.108316_bib278","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yjmcc.2019.09.012","article-title":"Effects of the combination of tanshinone IIA and puerarin on cardiac function and inflammatory response in myocardial ischemia mice","volume":"137","author":"Gao","year":"2019","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.phrs.2026.108316_bib279","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154283","article-title":"Tetrahydrocurcumin improves lipopolysaccharide-induced myocardial dysfunction by inhibiting oxidative stress and inflammation via JNK\/ERK signaling pathway regulation","volume":"104","author":"Zhu","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.phrs.2026.108316_bib280","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2020.112887","article-title":"Total flavonoids from Anchusa italica Retz. Improve cardiac function and attenuate cardiac remodeling post myocardial infarction in mice","volume":"257","author":"Wang","year":"2020","journal-title":"J. Ethnopharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108316_bib281","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/bcp.13536","article-title":"Ticagrelor attenuates myocardial ischaemia-reperfusion injury possibly through downregulating galectin-3 expression in the infarct area of rats","volume":"84","author":"Liu","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib282","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10840-019-00679-9","article-title":"Vildagliptin reduces myocardial ischemia-induced arrhythmogenesis via modulating inflammatory responses and promoting expression of genes regulating mitochondrial biogenesis in rats with type-II diabetes","volume":"59","author":"Yang","year":"2020","journal-title":"J. Interv. Card. Electrophysiol."},{"issue":"Pt 2","key":"10.1016\/j.phrs.2026.108316_bib283","article-title":"Dan-shen Yin attenuates myocardial fibrosis after myocardial infarction in rats: Molecular mechanism insights by integrated transcriptomics and network pharmacology analysis and experimental validation","volume":"338","author":"Gao","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.phrs.2026.108316_bib284","doi-asserted-by":"crossref","first-page":"36949","DOI":"10.1038\/srep36949","article-title":"Qishen granules inhibit myocardial inflammation injury through regulating arachidonic acid metabolism","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2026.108316_bib285","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2026.157784","article-title":"Qishen Yiqi Dropping Pills ameliorate acute myocardial infarction by modulating PKM2\/STAT3 pathway-mediated metabolic reprogramming in macrophages","volume":"151","author":"Fan","year":"2026","journal-title":"Phytomedicine"},{"key":"10.1016\/j.phrs.2026.108316_bib286","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2025.119456","article-title":"Sini decoction alleviates LPS-induced sepsis partly via restoration of metabolic impairments in the hypothalamic-pituitary-adrenal microenvironment","volume":"343","author":"Qiao","year":"2025","journal-title":"J. Ethnopharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib287","first-page":"148","article-title":"Sini decoction alleviates inflammation injury after myocardial infarction through regulating arachidonic acid metabolism","volume":"17","author":"Long","year":"2025","journal-title":"Chin. Herb. Med."},{"issue":"6","key":"10.1016\/j.phrs.2026.108316_bib288","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3892\/ijmm.2014.1950","article-title":"Xuebijing attenuates hypotension through the upregulation of angiotensin II type 1 receptor-associated protein 1 in rats suffering from heat stroke","volume":"34","author":"Pan","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.phrs.2026.108316_bib289","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.118740","article-title":"vivo and in vitro study on the regulatory mechanism of XiaoChaiHu decoction on PANoptosis in sepsis-induced cardiomyopathy","volume":"336","author":"Wang","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.phrs.2026.108316_bib290","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.118329","article-title":"Integrated serum pharmacochemistry with network pharmacology and pharmacological validation to elucidate the mechanism of yiqitongmai decoction (YQTMD) against myocardial infarction","volume":"331","author":"Yu","year":"2024","journal-title":"J. Ethnopharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108316_bib291","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13Ralpha2 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.phrs.2026.108316_bib292","article-title":"CAR-T cells in solid tumors: Challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell. Rep. Med."},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib293","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41577-025-01229-3","article-title":"Microenvironmental regulation of solid tumour resistance to CAR T cell therapy","volume":"26","author":"Lamplugh","year":"2026","journal-title":"Nat. Rev. Immunol."},{"issue":"39","key":"10.1016\/j.phrs.2026.108316_bib294","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202506429","article-title":"Synthetic Biology and Biomaterials Strategies to Deceive the Tumor Microenvironment in CAR-T Immunotherapy","volume":"21","author":"Marsico","year":"2025","journal-title":"Small"},{"issue":"7","key":"10.1016\/j.phrs.2026.108316_bib295","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s00262-023-03423-5","article-title":"IL13Ralpha2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy","volume":"72","author":"Gu","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"24","key":"10.1016\/j.phrs.2026.108316_bib296","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A Phase I\/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib297","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030660","article-title":"Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer","volume":"20","author":"Klapdor","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.phrs.2026.108316_bib298","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2026.108316_bib299","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0281735","article-title":"Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models","volume":"18","author":"Sawaisorn","year":"2023","journal-title":"PLoS. One"},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib300","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1158\/2159-8290.CD-22-0964","article-title":"CD19\/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive\/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"13","author":"Larson","year":"2023","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.phrs.2026.108316_bib301","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.trecan.2025.03.001","article-title":"The clinical landscape of CAR-engineered unconventional T cells","volume":"11","author":"Li","year":"2025","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib302","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","article-title":"The clinical landscape of CAR NK cells","volume":"14","author":"Jorgensen","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108316_bib303","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100804","article-title":"Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells","volume":"6","author":"Li","year":"2025","journal-title":"Med"},{"issue":"3","key":"10.1016\/j.phrs.2026.108316_bib304","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","article-title":"Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method","volume":"43","author":"Li","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108316_bib305","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1007\/s00277-025-06538-0","article-title":"Expanding the frontier of CAR therapy: comparative insights into CAR-T, CAR-NK, CAR-M, and CAR-DC approaches","volume":"104","author":"Zhang","year":"2025","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib306","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.1038\/s41467-023-43424-7","article-title":"Intrinsic factors and CD1d1 but not CD1d2 expression levels control invariant natural killer T cell subset differentiation","volume":"14","author":"Amable","year":"2023","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.phrs.2026.108316_bib307","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat. Med."},{"issue":"15","key":"10.1016\/j.phrs.2026.108316_bib308","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158242","article-title":"Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment","volume":"23","author":"Nenna","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2026.108316_bib309","article-title":"Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T)","volume":"9","author":"Burns","year":"2021","journal-title":"Ther. Recognit. Risk Factors Manag. Dis."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:37:18Z","timestamp":1785890238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826002318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":309,"alternative-id":["S1043661826002318"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108316","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor-T cell therapy-induced cardiotoxicity: Pathophysiological mechanisms and pharmacological intervention strategies","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108316"}}